EyePoint Pharmaceuticals, Inc. (EYPT)
Market Cap | 417.20M |
Revenue (ttm) | 50.02M |
Net Income (ttm) | -78.92M |
Shares Out | 52.08M |
EPS (ttm) | -1.81 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 803,221 |
Open | 8.31 |
Previous Close | 8.31 |
Day's Range | 7.73 - 8.43 |
52-Week Range | 5.67 - 30.99 |
Beta | 1.60 |
Analysts | Strong Buy |
Price Target | 32.80 (+309.49%) |
Earnings Date | Jul 31, 2024 |
About EYPT
EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in ... [Read more]
Financial Performance
In 2023, EYPT's revenue was $46.02 million, an increase of 11.14% compared to the previous year's $41.40 million. Losses were -$70.80 million, -30.77% less than in 2022.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for EYPT stock is "Strong Buy." The 12-month stock price forecast is $32.8, which is an increase of 309.49% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/3/w/press11-2483976.jpg)
EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024
WATERTOWN, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the...
![](https://cdn.snapi.dev/images/v1/e/b/press14-2481564.jpg)
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patie...
![](https://cdn.snapi.dev/images/v1/3/e/conf14-2463201.jpg)
EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference
WATERTOWN, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patie...
![](https://cdn.snapi.dev/images/v1/t/k/press10-2417517.jpg)
EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments
– Company on track to initiate the Phase 3 LUGANO pivotal non-inferiority trial of DURAVYU ™ in wet AMD in 2H 2024 –
![](https://cdn.snapi.dev/images/v1/w/q/im-684046size1777777777777778w-2412058.jpg)
EyePoint Pharmaceuticals' stock plunges as eye treatment fails to meet trial goal
Shares of EyePoint Pharmaceuticals Inc. EYPT, -1.00% dropped nearly 30% in premarket trading Monday after the company said its experimental retinal-disease treatment had failed to meet the primary goa...
![](https://cdn.snapi.dev/images/v1/t/d/press8-2411485.jpg)
EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy
– DURAVYU demonstrates stable or improved disease severity with reduced rates of NPDR progression at nine months –
![](https://cdn.snapi.dev/images/v1/p/h/press16-2351546.jpg)
EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists
- Charles Wykoff, M.D., Ph.D. joins Carl Regillo, M.D.
![](https://cdn.snapi.dev/images/v1/h/j/press6-2312729.jpg)
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments
– Announced positive topline efficacy and safety data from the Phase 2 DAVIO 2 trial of EYP-1901 in wet AMD achieving all primary and secondary endpoints; initiation of the first Phase 3 clinical tria...
![](https://cdn.snapi.dev/images/v1/v/x/press13-2305853.jpg)
EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer
– Company on-track to report topline data in 2Q 2024 for the Phase 2 PAVIA clinical trial of EYP-1901 in moderately severe-to-severe NPDR –
![](https://cdn.snapi.dev/images/v1/q/g/conf13-2300683.jpg)
EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024
WATERTOWN, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients ...
![](https://cdn.snapi.dev/images/v1/g/x/conf20-2295383.jpg)
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
WATERTOWN, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patie...
![](https://cdn.snapi.dev/images/v1/w/a/press10-2258941.jpg)
EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration
WATERTOWN, Mass., Feb. 03, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients w...
![](https://cdn.snapi.dev/images/v1/n/y/conf4-2252565.jpg)
EyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
WATERTOWN, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients w...
![](https://cdn.snapi.dev/images/v1/j/h/press19-2223646.jpg)
EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 VERONA Clinical Trial of EYP-1901 for the Treatment of Diabetic Macular Edema
WATERTOWN, Mass., Jan. 10, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients w...
![](https://cdn.snapi.dev/images/v1/l/t/conf6-2203167.jpg)
EyePoint Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
WATERTOWN, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients w...
![](https://cdn.snapi.dev/images/v1/j/p/press17-2189835.jpg)
EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares
WATERTOWN, Mass., Dec. 08, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients w...
![](https://cdn.snapi.dev/images/v1/j/b/press19-2184918.jpg)
EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering
WATERTOWN, Mass., Dec. 05, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients w...
![](https://cdn.snapi.dev/images/v1/s/h/eyepoint-2183480.jpeg)
EyePoint (EYPT) stock price went parabolic: brace for a pullback
EyePoint Pharmaceuticals (NASDAQ: EYPT) stock price has surged hard this week as it became a favorite among StockTwits traders. The shares jumped to a high of $22.40 on Monday, its highest point since...
![](https://cdn.snapi.dev/images/v1/7/6/biotech36-2182797.jpg)
EyePoint announces $175 million stock offering following record surge in share price
EyePoint Pharmaceuticals Inc. EYPT, +177.46% announced Monday afternoon that it has begun an underwritten public offering of $175 million in common stock. The company will also give underwriters the c...
![](https://cdn.snapi.dev/images/v1/y/j/press20-2182654.jpg)
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
WATERTOWN, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients w...
![](https://cdn.snapi.dev/images/v1/x/j/semi13-2181673.jpg)
EyePoint Pharmaceuticals' stock soars 362% after company announces positive data from trial of wet AMD treatment
EyePoint Pharmaceutics Inc.'s stock EYPT, +5.76% rocketed 362% early Monday, after the company announced positive results from a Phase 2 trial of its EYP-1901 treatment for wet age-related macular deg...
![](https://cdn.snapi.dev/images/v1/d/s/press11-2181529.jpg)
EyePoint Pharmaceuticals Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMD Achieving All Primary and Secondary Endpoints
– Both EYP-1901 cohorts demonstrated a statistically non-inferior change in BCVA versus aflibercept control with a numerical difference of only -0.3 and -0.4 letters, respectively for the 2 mg and 3 m...
![](https://cdn.snapi.dev/images/v1/z/r/press19-2132360.jpg)
EyePoint Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Developments
– Positive masked safety data update for EYP-1901 in ongoing PAVIA and DAVIO 2 Phase 2 clinical trials as of October 1, 2023 with no drug related ocular or systemic SAEs reported –
![](https://cdn.snapi.dev/images/v1/w/k/press14-2129836.jpg)
EyePoint Pharmaceuticals to Host Virtual Key Opinion Leader (KOL) Event on November 9, 2023
- KOLs to provide insight and discussion of EYP-1901 in wet AMD and topline data considerations for the DAVIO 2 clinical trial - KOLs to provide insight and discussion of EYP-1901 in wet AMD and topli...
![](https://cdn.snapi.dev/images/v1/o/v/press9-2127505.jpg)
EyePoint Pharmaceuticals Announces Presentations at Eyecelerator 2023, American Academy of Ophthalmology Annual Meeting 2023 and Guggenheim's 5th Annual Inflammation, Neurology & Immunology Conference 2023
WATERTOWN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the live...